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Abstract 
 
There is broad agreement that open-ended consent to research involving banked 
specimens and associated data is morally justifiable. Importantly, this approach is 
justifiable if, and only if, clear mechanisms are in place for 1.ethical and scientific 
oversight, and 2. ongoing communication with tissue donors. The problem for those 
in favour of open-ended consent for research is that biobanks have the greatest 
potential as resources for translational research if they are networked - both 
nationally and internationally. And as networks, by definition, require that 
custodianship of samples be relinquished at some point, this makes it difficult, if not 
impossible, to guarantee sound ethical and scientific oversight and to promise 
ongoing communication with donors. Unless the reality of globalisation is addressed 
head on, even the most thoughtful ethical proposals, such as that put forward in this article, 
will soon be obsolete. 
 
 
There is broad agreement among researchers, biobankers and ethicists that open-ended 
consent to research involving banked specimens and associated data provides 
the best means for optimising the enormous potential of biobanks. In a synthesis we 
conducted in 2011 of empirical sociological studies of biobanking, we found that 
while most people wanted to be asked, at least initially, about the use of their tissue 
in research, they generally did not want large amounts of information, and were 
willing to give open-ended consent (Lipworth, Forsyth, and Kerridge 2011)—a finding 
consistent with numerous other studies (Lipworth, Ankeny, and Kerridge 2006, 
Lipworth, Forsyth, and Kerridge 2011, Lipworth et al. 2009, Morrell et al. 2011) and 
with Grady et al, who concluded that that open-ended consent to biobanking 
research was consistent with community preferences. 
 
Also like Grady et al., we concluded from our synthesis that open-ended consent is 
morally justifiable if, and only if, clear mechanisms are in place for 1.ethical and 
scientific oversight, and 2. ongoing communication with tissue donors. Specifically, 
we found a widespread expectation that general feedback and aggregated results 
would be provided in exchange for participation, and that all biobanks should have in 
place formal mechanisms—including institutional review committees and public 
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consultation—for controlling biobank resources (Lipworth, Forsyth, and Kerridge 
2011). 
 
While it is attractive in theory to promise ongoing ethical oversight and 
communication in exchange for participation and open-ended consent, the reality is 
that that it might no longer be possible to make such promises. This is because 
biobanks are increasingly networked - both nationally and internationally. This, in 
turn, makes it difficult, if not impossible, to guarantee sound ethical and scientific 
oversight of biobanks and to promise ongoing communication with donors. 
It could be argued that biobanks should simply not be networked so that these 
ethical conditions can be met, but global biobank networks have become a scientific 
necessity for certain kinds of research. For example, large numbers of samples are 
needed for longitudinal analyses of healthy populations (where numerous samples 
need to be analysed in order to identify relevant genetic variants); for the study of 
rare diseases; for the study of common but complex, multigenic disorders such as 
cancer and heart disease; for global multi-centre clinical trials that require testing of 
fresh tissue; and in cases where it is socio-culturally or practically difficult to obtain 
tissue—for example the collection of postmortem brain tissue. Pharmaceutical 
companies also need large networks of biobanks in order to meet the regulatory 
requirement that they study samples and data from populations of different ethnic 
origins in the course of their clinical trials. Furthermore, the development of biobank 
networks is important for economic and practical reasons, because single biobanks, 
particularly those maintained by single institutions, are rarely sustainable and are 
inefficient – duplicating the resources and activities of other similar biobanks 
(Catchpoole et al. 2007). 
 
Given the scientific, economic and practical necessity of biobank networks, and their 
corresponding rapid growth, it is not sufficient, as Grady and colleagues do, to simply 
state that further research is needed to “assess the applicability of this proposal to 
international sample collection”. Instead of a simple caveat at the end of a policy 
report, what is needed is a systematic program of research and policymaking that 
addresses head-on the many technical, governance, legal and ethical challenges that 
arise when research is no longer constrained by institutional, academic, cultural or 
national boundaries. 
 
Some of the technical, governance and legal challenges posed by the networking of 
bioabanks that will need to be addressed include: the funding of biobank networks; 
the technical standardization and quality control of tissue collection, storage and 
annotation; the institution of policies on intellectual property, and the sharing of 
specimens and data (Smith 2011). International networks of biobanks also rely upon 
some degree of regulatory harmonisation because restrictive national regulations 
prohibiting, or limiting, the import or export of human tissue samples, and lack of 
regulatory consistency across jurisdictions can be major barriers to the transfer of 
tissue across borders (Hoeyer 2012). 
 
There are also a number of ethical concerns that will need to be addressed if global 
biobanking is to succeed. While many of these issues—including consent, 
commercialisation, privacy, treatment of tissue, return of results, community 
involvement, benefit sharing, or “ownership”—are also raised by individual 
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biobanks, each of these issues becomes exponentially more complex when research 
is globalised and tissues are shared across borders (Hoeyer 2012, Smith 2011). 
 
Ultimately the major challenges that the globalization and networking of biobanks 
may raise is to community values such as trust, custodianship, benefit sharing, 
equity, respect for cultural difference and individual or community control over the 
use of their tissue and information. (Aparicio et al. 2013, Stewart et al. 2014). We 
know, for example, that trust and control are particular issues for indigenous 
communities around the world, who have concerns regarding the spiritual and 
cultural implications of donating human tissue, overstated promises made by 
researchers, the diversion of attention and resources away from addressing social 
determinants of health, and exploitation of communities who donate tissue but do 
not benefit from the results (Jacobs et al. 2010). 
 
Given that scientific and therapeutic advances are increasingly dependent upon 
biobanks; and that the creation of international networks of biobanks is necessary to 
optimise their benefits; then it is essential that we: 
 
1. Understand whether and how globalization and networking of biobanks 
challenge the values and principles upon which biobanks have been 
developed, and the processes and practices that have been established by 
successful ‘local’ biobanks; and 
 
2. Establish new mechanisms to manage the ethical and legal challenges to the 
networking of biobanks. 
 
Unless we understand and respond directly to the challenges raised by the 
globalization and networking of biobanks, there is a real possibility that biobank 
networks will be insufficiently cognizant of community values and fail to gain the 
trust needed for long-term viability. 
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